Journal Article
. 2018 Jan; 7(2):e1387705.
doi: 10.1080/2162402X.2017.1387705.

Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis

Luigi Cari 1 Giuseppe Nocentini 1 Graziella Migliorati 1 Carlo Riccardi 1 
Affiliations
  • PMID: 29308313
  •     77 References
  •     14 citations

Abstract

One of the mechanisms of tumor rejection in immune-modulatory treatments is antibody-dependent cell-mediated cytotoxicity (ADCC) of regulatory T cells (Tregs) that infiltrate tumors in which cells expressing activating Fcγ receptors (FcγRs) are present. Our objective was to identify, through a bioinformatics analysis, Treg marker(s) expressed at the highest levels in nine types of human cancers, in order to determine the best targets for ADCC-inducing antitumor antibodies. We analyzed the mRNA levels of 24 surface Treg markers evaluated by the Affymetrix Human Genome U133 Plus 2.0 Array in 5728 cancer samples obtained via the Genevestigator v3 suite. Our analysis was based on overexpression of markers in tumors as compared to healthy tissues (HTs) and correlation between overexpression of the markers and the tumor suppressive microenvironment. Moreover, we evaluated tumoral infiltration of activating FcγR-expressing cells and calculated the ADCC index for each overexpressed marker, as an indicator of whether the marker was a good target for ADCC induction in tumor-infiltrating Tregs. The results demonstrated that the ADCC strategy is unlikely to succeed in colorectal, liver, prostate and ovarian cancers. Moreover, we identified nine Treg markers that could be targeted in the other tumors: 4-1BB, CD39, galectin-9, GITR, IL-21R, LAP, neuropilin-1, TIGIT and TNFR2. GITR and TIGIT were the only markers that could be potentially useful as targets for the treatment of three cancers: non-squamous and squamous NSCLC and breast infiltrating ductal carcinoma. LAP, neuropilin-1 and CD39 presented as good targets in the treatment of renal cell carcinoma. Our findings may have value for the development of new anti-tumor antibodies.

Keywords: CD39; GITR; LAP; TIGIT; Treg marker; activating Fcγ receptors; antibody-dependent cell-mediated cytotoxicity; bioinformatics; human cancer; neuropilin-1.

Tregs and rethinking cancer immunotherapy.
Tyler J Curiel.
J Clin Invest, 2007 May 04; 117(5). PMID: 17476346    Free PMC article.
Highly Cited. Review.
Tumor necrosis factor receptor expression and signaling in renal cell carcinoma.
Rafia S Al-Lamki, Timothy J Sadler, +10 authors, John R Bradley.
Am J Pathol, 2010 Jun 23; 177(2). PMID: 20566746    Free PMC article.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.
Markus Feuerer, Jonathan A Hill, Diane Mathis, Christophe Benoist.
Nat Immunol, 2009 Jun 19; 10(7). PMID: 19536194
Highly Cited. Review.
ArrayExpress update--simplifying data submissions.
Nikolay Kolesnikov, Emma Hastings, +15 authors, Alvis Brazma.
Nucleic Acids Res, 2014 Nov 02; 43(Database issue). PMID: 25361974    Free PMC article.
Highly Cited.
Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
A Aruga, E Aruga, +3 authors, A E Chang.
J Immunol, 1997 Jul 15; 159(2). PMID: 9218581
Rationale for anti-GITR cancer immunotherapy.
Deborah A Knee, Becker Hewes, Jennifer L Brogdon.
Eur J Cancer, 2016 Sep 04; 67. PMID: 27591414
Highly Cited. Review.
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Rebecca Leyland, Amanda Watkins, +19 authors, Ross Stewart.
Clin Cancer Res, 2017 Jan 11; 23(13). PMID: 28069723
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.
Etienne Becht, Nicolas A Giraldo, +8 authors, Aurélien de Reyniès.
Genome Biol, 2016 Oct 22; 17(1). PMID: 27765066    Free PMC article.
Highly Cited.
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Heather Torrey, John Butterworth, +10 authors, Denise L Faustman.
Sci Signal, 2017 Jan 18; 10(462). PMID: 28096513
Highly Cited.
Anti-GITR therapy promotes immunity against malignant glioma in a murine model.
Jason Miska, Aida Rashidi, +4 authors, Maciej S Lesniak.
Cancer Immunol Immunother, 2016 Oct 14; 65(12). PMID: 27734112    Free PMC article.
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
WanJun Chen, Wenwen Jin, +5 authors, Sharon M Wahl.
J Exp Med, 2003 Dec 17; 198(12). PMID: 14676299    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors: a patent review (2010-2015).
Matthieu Collin.
Expert Opin Ther Pat, 2016 Apr 08; 26(5). PMID: 27054314
Review.
Identification and characterization of latency-associated peptide-expressing γδ T cells.
Rafael M Rezende, Andre P da Cunha, +14 authors, Howard L Weiner.
Nat Commun, 2015 Dec 09; 6. PMID: 26644347    Free PMC article.
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.
Nicola Gagliani, Chiara F Magnani, +14 authors, Maria-Grazia Roncarolo.
Nat Med, 2013 Apr 30; 19(6). PMID: 23624599
Highly Cited.
Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Young H Kim, Su M Shin, +7 authors, Byoung S Kwon.
J Immunol, 2015 Oct 02; 195(10). PMID: 26423152
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.
Rodolfo Bianchini, Onelia Bistoni, +7 authors, Carlo Riccardi.
Eur J Immunol, 2011 May 11; 41(8). PMID: 21557210
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.
Nicole Joller, Jason P Hafler, +5 authors, Vijay K Kuchroo.
J Immunol, 2011 Jan 05; 186(3). PMID: 21199897    Free PMC article.
Highly Cited.
TGFbeta in Cancer.
Joan Massagué.
Cell, 2008 Jul 30; 134(2). PMID: 18662538    Free PMC article.
Highly Cited. Review.
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Pornpimol Charoentong, Francesca Finotello, +5 authors, Zlatko Trajanoski.
Cell Rep, 2017 Jan 05; 18(1). PMID: 28052254
Highly Cited.
Targeting latency-associated peptide promotes antitumor immunity.
Galina Gabriely, Andre P da Cunha, +15 authors, Howard L Weiner.
Sci Immunol, 2017 Aug 02; 2(11). PMID: 28763794    Free PMC article.
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.
May Abd Al Samid, Belal Chaudhary, +2 authors, Eyad Elkord.
Oncotarget, 2016 Feb 18; 7(12). PMID: 26885615    Free PMC article.
Targeting regulatory T cells in tumors.
Chang Liu, Creg J Workman, Dario A A Vignali.
FEBS J, 2016 Jan 21; 283(14). PMID: 26787424
Highly Cited. Review.
tTregs, pTregs, and iTregs: similarities and differences.
Ethan M Shevach, Angela M Thornton.
Immunol Rev, 2014 Apr 10; 259(1). PMID: 24712461    Free PMC article.
Highly Cited. Review.
Natural innate and adaptive immunity to cancer.
Matthew D Vesely, Michael H Kershaw, Robert D Schreiber, Mark J Smyth.
Annu Rev Immunol, 2011 Jan 12; 29. PMID: 21219185
Highly Cited. Review.
Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis.
Mei-Ling Chen, Bo-Shiun Yan, +2 authors, Howard L Weiner.
J Immunol, 2008 May 21; 180(11). PMID: 18490732    Free PMC article.
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.
Axel C P Diederichsen, J v B Hjelmborg, +2 authors, Claus Fenger.
Cancer Immunol Immunother, 2003 Apr 16; 52(7). PMID: 12695859
Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?
Theresa L Whiteside.
Cancer Immunol Immunother, 2013 Nov 12; 63(1). PMID: 24213679    Free PMC article.
Highly Cited. Review.
Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes.
Tomas Hruz, Oliver Laule, +6 authors, Philip Zimmermann.
Adv Bioinformatics, 2008 Jan 01; 2008. PMID: 19956698    Free PMC article.
Highly Cited.
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Chindu Govindaraj, Karen Scalzo-Inguanti, +4 authors, Magdalena Plebanski.
Clin Immunol, 2013 Aug 21; 149(1). PMID: 23948613
In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes.
Cristiano Sacchetti, Novella Rapini, +6 authors, Massimo Bottini.
Bioconjug Chem, 2013 May 21; 24(6). PMID: 23682992
Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells.
Shawn A Mahmud, Luke S Manlove, +10 authors, Michael A Farrar.
Nat Immunol, 2014 Mar 19; 15(5). PMID: 24633226    Free PMC article.
Highly Cited.
The head and neck cancer immune landscape and its immunotherapeutic implications.
Rajarsi Mandal, Yasin Şenbabaoğlu, +8 authors, Luc Gt Morris.
JCI Insight, 2016 Oct 26; 1(17). PMID: 27777979    Free PMC article.
Highly Cited.
Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Patrick J Schuler, Bastian Schilling, +4 authors, Theresa L Whiteside.
Eur J Immunol, 2012 May 16; 42(7). PMID: 22585562    Free PMC article.
CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.
Nathalie Bonnefoy, Jérémy Bastid, +2 authors, Jean-François Eliaou.
Oncoimmunology, 2015 Jul 15; 4(5). PMID: 26155397    Free PMC article.
Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.
Simona Ronchetti, Erika Ricci, +4 authors, Carlo Riccardi.
J Immunol Res, 2015 May 12; 2015. PMID: 25961057    Free PMC article.
Review.
Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells.
M Scurr, K Ladell, +10 authors, A Godkin.
Mucosal Immunol, 2013 Sep 26; 7(2). PMID: 24064667    Free PMC article.
IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.
Heba A Alshaker, Khalid Z Matalka.
Cancer Cell Int, 2011 Sep 29; 11. PMID: 21943203    Free PMC article.
Bioconductor: open software development for computational biology and bioinformatics.
Robert C Gentleman, Vincent J Carey, +22 authors, Jianhua Zhang.
Genome Biol, 2004 Oct 06; 5(10). PMID: 15461798    Free PMC article.
Highly Cited.
Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells.
Chuan Wu, Theresa Thalhamer, +7 authors, Vijay K Kuchroo.
Immunity, 2014 Jul 30; 41(2). PMID: 25065622    Free PMC article.
Highly Cited.
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, +2 authors, Nir Hacohen.
Cell, 2015 Jan 17; 160(1-2). PMID: 25594174    Free PMC article.
Highly Cited.
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer.
Chiao-Wen Kang, Avijit Dutta, +8 authors, Chun-Yen Lin.
Sci Rep, 2015 Oct 27; 5. PMID: 26493689    Free PMC article.
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
R A Clynes, T L Towers, L G Presta, J V Ravetch.
Nat Med, 2000 Mar 31; 6(4). PMID: 10742152
Highly Cited.
Phenotypical and functional specialization of FOXP3+ regulatory T cells.
Daniel J Campbell, Meghan A Koch.
Nat Rev Immunol, 2011 Jan 27; 11(2). PMID: 21267013    Free PMC article.
Highly Cited. Review.
Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection.
Cacilda Tezelli Junqueira Padovani, Camila Mareti Bonin, +3 authors, Izaias Pereira da Costa.
Rev Soc Bras Med Trop, 2013 Jul 17; 46(3). PMID: 23856878
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller, Ester Lozano, +13 authors, Vijay K Kuchroo.
Immunity, 2014 Apr 22; 40(4). PMID: 24745333    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Induced regulatory T cells in inhibitory microenvironments created by cancer.
Theresa L Whiteside.
Expert Opin Biol Ther, 2014 Jun 18; 14(10). PMID: 24934899    Free PMC article.
Review.
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Yannick Bulliard, Rose Jolicoeur, +3 authors, Jennifer L Brogdon.
Immunol Cell Biol, 2014 Apr 16; 92(6). PMID: 24732076
Highly Cited.
Regulatory T Cells: Differentiation and Function.
George Plitas, Alexander Y Rudensky.
Cancer Immunol Res, 2016 Sep 04; 4(9). PMID: 27590281    Free PMC article.
Highly Cited. Review.
The role of GITR single-positive cells in immune homeostasis.
Giuseppe Nocentini, Luigi Cari, Graziella Migliorati, Carlo Riccardi.
Immun Inflamm Dis, 2017 Mar 03; 5(1). PMID: 28250919    Free PMC article.
Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Giuseppe Nocentini, Luigi Cari, Simona Ronchetti, Carlo Riccardi.
Expert Opin Ther Pat, 2015 Nov 13; 26(3). PMID: 26560753
Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies.
Shravan Madireddi, So-Young Eun, +7 authors, Michael Croft.
J Exp Med, 2014 Jun 25; 211(7). PMID: 24958847    Free PMC article.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Gabriela Bindea, Bernhard Mlecnik, +14 authors, Jérôme Galon.
Immunity, 2013 Oct 22; 39(4). PMID: 24138885
Highly Cited.
TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, +6 authors, Ana C Anderson.
J Clin Invest, 2015 Sep 29; 125(11). PMID: 26413872    Free PMC article.
Highly Cited.
Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells.
Hiromasa Morikawa, Shimon Sakaguchi.
Immunol Rev, 2014 Apr 10; 259(1). PMID: 24712467
Highly Cited. Review.
Digital genomic quantification of tumor-infiltrating lymphocytes.
Harlan S Robins, Nolan G Ericson, +4 authors, Jason H Bielas.
Sci Transl Med, 2013 Dec 07; 5(214). PMID: 24307693    Free PMC article.
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.
Marco De Simone, Alberto Arrigoni, +28 authors, Massimiliano Pagani.
Immunity, 2016 Nov 17; 45(5). PMID: 27851914    Free PMC article.
Highly Cited.
GITR+ regulatory T cells in the treatment of autoimmune diseases.
Maria Grazia Petrillo, Simona Ronchetti, +4 authors, Carlo Riccardi.
Autoimmun Rev, 2014 Dec 03; 14(2). PMID: 25449679
Review.
Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability.
Daniel B Rifkin.
J Biol Chem, 2004 Dec 22; 280(9). PMID: 15611103
Highly Cited. Review.
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
Udaya K Liyanage, Todd T Moore, +8 authors, David C Linehan.
J Immunol, 2002 Aug 24; 169(5). PMID: 12193750
Highly Cited.
The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon.
Nat Rev Cancer, 2012 Mar 16; 12(4). PMID: 22419253
Highly Cited. Review.
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Kuibeom Ko, Sayuri Yamazaki, +7 authors, Shimon Sakaguchi.
J Exp Med, 2005 Sep 28; 202(7). PMID: 16186187    Free PMC article.
Highly Cited.
Profiling networks of distinct immune-cells in tumors.
Trevor Clancy, Eivind Hovig.
BMC Bioinformatics, 2016 Jul 06; 17(1). PMID: 27377892    Free PMC article.
Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
Meimei Bu, Yizhen Shen, +4 authors, Yan Cai.
Tumour Biol, 2015 Oct 21; 37(3). PMID: 26482613
Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
N Seo, S Hayakawa, M Takigawa, Y Tokura.
Immunology, 2001 Sep 01; 103(4). PMID: 11529935    Free PMC article.
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
E Y Woo, C S Chu, +6 authors, C H June.
Cancer Res, 2001 Jun 19; 61(12). PMID: 11406550
Highly Cited.
Natural and induced T regulatory cells in cancer.
Dennis O Adeegbe, Hiroyoshi Nishikawa.
Front Immunol, 2013 Jul 23; 4. PMID: 23874336    Free PMC article.
Highly Cited.
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.
George Plitas, Catherine Konopacki, +5 authors, Alexander Y Rudensky.
Immunity, 2016 Nov 17; 45(5). PMID: 27851913    Free PMC article.
Highly Cited.
GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells.
Dat Q Tran, John Andersson, +3 authors, Ethan M Shevach.
Proc Natl Acad Sci U S A, 2009 Aug 05; 106(32). PMID: 19651619    Free PMC article.
Highly Cited.
NCBI GEO: mining millions of expression profiles--database and tools.
Tanya Barrett, Tugba O Suzek, +7 authors, Ron Edgar.
Nucleic Acids Res, 2004 Dec 21; 33(Database issue). PMID: 15608262    Free PMC article.
Highly Cited.
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer.
Alessia Burocchi, Mario P Colombo, Silvia Piconese.
Front Immunol, 2013 Aug 30; 4. PMID: 23986759    Free PMC article.
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Christopher A Fuhrman, Wen-I Yeh, +15 authors, Todd M Brusko.
J Immunol, 2015 May 23; 195(1). PMID: 25994968    Free PMC article.
Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications.
Maria Grazia Roncarolo, Silvia Gregori, Rosa Bacchetta, Manuela Battaglia.
Curr Top Microbiol Immunol, 2014 Jul 10; 380. PMID: 25004813
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
Aurélien Marabelle, Holbrook Kohrt, +13 authors, Ronald Levy.
J Clin Invest, 2013 Jun 04; 123(6). PMID: 23728179    Free PMC article.
Highly Cited.
TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.
Yuqiao Sheng, Feng Li, Zhihai Qin.
Front Immunol, 2018 Jun 13; 9. PMID: 29892300    Free PMC article.
Review.
Identification of Six Potentially Long Noncoding RNAs as Biomarkers Involved Competitive Endogenous RNA in Clear Cell Renal Cell Carcinoma.
Kang Yang, Xiao-Fan Lu, Peng-Cheng Luo, Jie Zhang.
Biomed Res Int, 2018 Nov 09; 2018. PMID: 30406146    Free PMC article.
Identification of 15 T Cell Restricted Genes Evaluates T Cell Infiltration of Human Healthy Tissues and Cancers and Shows Prognostic and Predictive Potential.
Luigi Cari, Francesca De Rosa, +3 authors, Carlo Riccardi.
Int J Mol Sci, 2019 Oct 28; 20(20). PMID: 31652661    Free PMC article.
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Isaure Vanmeerbeek, Jenny Sprooten, +8 authors, Abhishek D Garg.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002302    Free PMC article.
Review.
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker.
Yan Wen Zhang, Qian Qian Chen, +5 authors, Li Xia Dong.
Thorac Cancer, 2019 Jan 11; 10(3). PMID: 30628200    Free PMC article.
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
Chunxiao Li, Ping Jiang, +2 authors, Junjie Wang.
Mol Cancer, 2020 Jul 19; 19(1). PMID: 32680511    Free PMC article.
Review.
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.
Sebastian Chrétien, Ioannis Zerdes, +2 authors, Theodoros Foukakis.
Cancers (Basel), 2019 May 08; 11(5). PMID: 31060337    Free PMC article.
Review.
miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8.
Ting Liu, Jingjing Meng, Yu Zhang.
Mol Med Rep, 2020 Sep 19; 22(4). PMID: 32945439    Free PMC article.
Context-Dependent Effect of Glucocorticoids on the Proliferation, Differentiation, and Apoptosis of Regulatory T Cells: A Review of the Empirical Evidence and Clinical Applications.
Luigi Cari, Francesca De Rosa, Giuseppe Nocentini, Carlo Riccardi.
Int J Mol Sci, 2019 Mar 09; 20(5). PMID: 30845709    Free PMC article.
Review.
Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma.
Giovanni Cochetti, Luigi Cari, +5 authors, Ettore Mearini.
Sci Rep, 2020 Dec 06; 10(1). PMID: 33277569    Free PMC article.
Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
Mayanne M T Zhu, Samantha Burugu, +5 authors, Torsten O Nielsen.
Mod Pathol, 2020 May 01; 33(9). PMID: 32350416
Targeting neuropilin-1 interactions is a promising anti-tumor strategy.
Shao-Dan Liu, Li-Ping Zhong, Jian He, Yong-Xiang Zhao.
Chin Med J (Engl), 2020 Nov 13; 134(5). PMID: 33177389    Free PMC article.
Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer.
Qiang Fu, Qian Shen, +3 authors, Wei Zhong.
Front Cell Dev Biol, 2021 Dec 14; 9. PMID: 34900985    Free PMC article.
Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.
Muchun Li, Xiaozhen Zhang, Xueli Bai, Tingbo Liang.
Front Oncol, 2022 May 03; 12. PMID: 35494080    Free PMC article.
Review.